A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

July 27, 2021

Study Completion Date

July 27, 2021

Conditions
Breast CancerCancer
Interventions
BIOLOGICAL

Nivolumab

Specified Dose on Specified Days

DRUG

Anastrozole

Specified Dose on Specified Days

DRUG

Palbociclib

Specified Dose on Specified Days

Trial Locations (36)

2610

Local Institution - 0011, Wilrijk

4000

Local Institution, Liège

5000

Local Institution, Namur

5112

Local Institution - 0005, Elizabeth Vale

6009

Breast Cancer Research Centre - WA, Nedlands

13273

Local Institution - 0019, Marseille

22408

Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg

23601

Peninsula Cancer Institute, Newport News

28041

Hosp Univer 12 De Octubre, Madrid

29010

Hospital Universitario Virgen De La Victoria, Málaga

30342

Northside Hospital,Inc.- Central Research Department, Atlanta

30607

University Cancer Blood Ctr, Athens

31059

Institut Claudius Regaud, Toulouse

33077

Local Institution - 0075, Bordeaux

34070

Centre de Cancerologie du Grand Montpellier, Montpellier

41013

Hospital Universitario Virgen Del Rocio, Seville

41061

Local Institution, Mönchengladbach

44109

MetroHealth Medical Center, Cleveland

45136

Klinik Essen-Mitte, Essen

46010

Hospital Clinico Universitario De Valencia, Valencia

53111

Local Institution, Bonn

60611

Northwestern University, Chicago

66113

Local Institution, Saarbrücken

69373

Centre Leon Berard, Lyon

85925

Local Institution - 0072, La Roche-sur-Yon

90603

Local Institution - 0031, Whittier

91054

Local Institution, Erlangen

94010

Local Institution - 0073, Créteil

07932

Local Institution - 0041, Florham Park

07601

The Cancer Center At Hackensack University Medical Center, Hackensack

K1H 8L6

Local Institution - 0071, Ottawa

00731

Local Institution - 0047, Monterrey Ponce

00927

Local Institution - 0002, San Juan

00936

Local Institution - 0062, San Juan

08035

H. Univ. Vall dHebron, Barcelona

08036

Local Institution - 0037, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04075604 - A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | Biotech Hunter | Biotech Hunter